{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:03:25Z","timestamp":1777431805160,"version":"3.51.4"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[1995,4,1]],"date-time":"1995-04-01T00:00:00Z","timestamp":796694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1995,4]]},"abstract":"<jats:p>The in vitro activity of a prototype 2-aryl carbapenem, L-695,256, against gram-positive bacteria was examined. All streptococci and oxacillin-susceptible and -resistant staphylococci were inhibited at concentrations of &lt; or = 0.125, &lt; or = 0.125, and 4 micrograms\/ml, respectively. The activity of L-695,256 was superior to that of imipenem against other organisms intrinsically resistant to beta-lactams.<\/jats:p>","DOI":"10.1128\/aac.39.4.990","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:06:25Z","timestamp":1340841985000},"page":"990-995","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":13,"title":["Comparative in vitro activities of L-695,256, a novel carbapenem, against gram-positive bacteria"],"prefix":"10.1128","volume":"39","author":[{"given":"G","family":"Malanoski","sequence":"first","affiliation":[{"name":"Department of Medicine, Deaconess Hospital, Boston, Massachusetts 02215, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Medicine, Deaconess Hospital, Boston, Massachusetts 02215, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C T","family":"Eliopoulos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Deaconess Hospital, Boston, Massachusetts 02215, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"R C","family":"Moellering","sequence":"additional","affiliation":[{"name":"Department of Medicine, Deaconess Hospital, Boston, Massachusetts 02215, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G M","family":"Eliopoulos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Deaconess Hospital, Boston, Massachusetts 02215, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.39.4.990","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.39.4.990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:01:22Z","timestamp":1645473682000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.39.4.990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,4]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1995,4]]}},"alternative-id":["10.1128\/AAC.39.4.990"],"URL":"https:\/\/doi.org\/10.1128\/aac.39.4.990","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,4]]},"assertion":[{"value":"1995-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}